AOD-9604 is sold online as a fat-targeting peptide with a growth-hormone pedigree and none of growth hormone’s downsides. The pedigree part is real. A peer-reviewed human trial showing it reduces fat in people is not, at least not one that turns up in a literature search. What does exist is a specific, carefully designed 2001 mouse study and a 15-amino-acid fragment of human growth hormone with a mechanism that is genuinely interesting and only partly understood. Those are not the same thing as evidence that AOD-9604 works in humans, and the gap between them is the actual story.
What happened to the human trial
By 2004, drug-development trackers still listed AOD-9604 as an early-stage compound. A pipeline summary from that year, covering the development program at Metabolic Pharmaceuticals, notes that phase IIa trials for obesity were underway as of February 2002. It reports no result.[1]
That’s it. That’s the entire trail.
No published, peer-reviewed trial in the searchable literature reports what those phase IIa trials, or anything run afterward, found about body weight or fat mass in people. Not a positive result, not a negative one, not a null one. Marketing pages that cite “the AOD-9604 clinical trial” are pointing at a gap, not a finding.
A phase IIa trial is a small, early efficacy study, the stage a drug reaches after safety testing but before the larger trials regulators weigh for approval. Plenty of compounds enter phase IIa and never clear it, and that alone wouldn’t be unusual. What’s unusual is that nobody appears to have published what stalling looked like for AOD-9604, so the public record simply stops mid-sentence.
Bottom line: the human evidence trail runs out at “trials were underway” in a 2004 pipeline note. Nothing published since establishes what AOD-9604 does to a person’s weight or body fat.
The mouse study that exists
The real efficacy data on AOD-9604 comes from a 2001 Endocrinology paper by Heffernan and colleagues, and it holds up as careful work.[2] Obese mice given daily intraperitoneal injections of AOD-9604 for 14 days lost body weight and body fat, matching what full-length human growth hormone did in the same experiment.
14 days of daily injections in the only controlled efficacy study of AOD-9604 (mice, not humans) PMID 11713213
The researchers didn’t stop at “it worked.” They bred beta(3)-adrenergic receptor knockout mice to find out why. Given the same chronic dosing schedule, AOD-9604 and hGH stopped producing weight loss in those knockout animals entirely.[2] On its own, that result reads like confirmation that the beta(3)-adrenergic receptor is the mechanism, but the same paper complicates that reading.
AOD-9604 is the fragment on the right, not the full hormone.
A receptor puzzle the same study raises and never closes
Here’s the wrinkle the paper itself reports: even though the chronic weight-loss effect required the beta(3)-adrenergic receptor to be present, the compounds’ lipolytic action is not mediated directly through that receptor.[2] AOD-9604 does increase expression of the receptor, and in a short acute experiment it still raised energy expenditure and fat oxidation in the knockout mice, receptor or no receptor.
So the honest mechanistic picture is unresolved. Something about chronic AOD-9604 exposure needs an intact beta(3)-adrenergic pathway to produce sustained weight loss in mice, but the drug’s direct lipolytic signal doesn’t run through that receptor. That is not a settled mechanism. It is a question one mouse study raised in 2001 that nothing since has answered.
Antilipogenic, not lipolytic: what the 1993 study found
AOD-9604 corresponds to the C-terminal fragment of human growth hormone, residues 177 to 191, and a 1993 study by Wu and Ng first localized a specific metabolic activity to that stretch of the molecule.[3] The finding is more precise than the marketing language suggests. The isolated fragment reproduced growth hormone’s antilipogenic action, blocking new fat formation, but the same study found no significant lipolytic effect (fat breakdown, measured by glycerol release from rat fat pads) from the fragment alone.[3]
That distinction is worth sitting with, because “lipolytic fragment” is the phrase used throughout the later AOD-9604 literature, including in the title of the 2001 mouse paper itself.[2] The original 1993 characterization found the opposite for lipolysis specifically. Both things can be true at once: the isolated fragment retains a real piece of growth hormone’s fat metabolism, and calling it “the lipolytic fragment” oversimplifies a more complicated 30-year-old dataset.
The fragment itself is small, just 15 amino acids carved out of a much larger hormone, without the receptor-binding domains that give full-length growth hormone its growth-promoting effects.[3]
Dosing and safety: documented in mice, undocumented in people
What’s published is a mouse protocol, not a human one.
Species: obese mice, not humans[2]
Route: daily intraperitoneal injection[2]
Duration: 14 days of chronic treatment[2]
Stated purpose: testing lipolytic and metabolic effects, not establishing a human dose[2]
No source turned up in this search documents a dosing schedule used in an AOD-9604 human study, a tolerability record from a completed human trial, or a comparison of AOD-9604’s glucose and insulin effects against unmodified growth hormone in people. That’s not a minor gap.
The real risk: anyone measuring out a specific AOD-9604 dose today is following a protocol lifted from a 2001 mouse study, not a human trial that ever established a safe or effective dose in people.
Where AOD-9604 sits against peptides that have actual human trials
The contrast with better-documented compounds is not subtle.
The published human evidence, compound by compound
Compound | Published human RCT | What it showed |
|---|---|---|
AOD-9604 | None located | Mouse efficacy data only (2001); human trials reported as "underway" in 2004, no result published since |
Semaglutide | STEP 2 trial | Significantly greater weight loss than placebo in adults with overweight or obesity and type 2 diabetes |
Tesamorelin | 412-patient RCT (Falutz et al. 2007) | Significantly reduced visceral adipose tissue versus placebo over 26 weeks in HIV-associated fat accumulation |
Restricted to the trials cited in this article.
Semaglutide’s weight-loss claim rests on trials like the randomized, double-blind, double-dummy, placebo-controlled STEP 2 trial, which found significantly greater weight loss with the drug than with placebo in adults with overweight or obesity and type 2 diabetes.[4] Natural Peptides: Which Claims Have Human Trials covers how uneven the evidence base is across this category generally. AOD-9604 sits at the thin end of it.
Tesamorelin is the closer comparison, since it’s also a modified growth-hormone-axis peptide marketed partly on body-composition claims. In a randomized, placebo-controlled trial of 412 HIV-infected patients, tesamorelin significantly reduced visceral adipose tissue over 26 weeks compared with placebo.[5] Whatever you think of tesamorelin’s off-label uses, which our tesamorelin explainer covers in more depth, that is a real trial with a real primary endpoint behind it. AOD-9604 has no equivalent to point to.
GHK-Cu runs on a similar split between mechanism and proof, which our review of its evidence base lays out for a different peptide entirely. The pattern shows up often enough in this category that it deserves a name: a real, specific animal or mechanism paper gets treated in marketing copy as if it were a human efficacy trial, and nobody checks whether the second thing was ever published.
The comparison that matters: tesamorelin and semaglutide each have a named, citable human trial behind their headline claim. AOD-9604 has a mouse study and a phase IIa status update from 2004.
What the evidence does not establish
To be direct about the gaps:
It does not establish that AOD-9604 reduces fat in humans. The only controlled efficacy data sits in mice.
It does not establish a human dose. No published source ties a specific AOD-9604 amount to a measured human outcome.
It does not establish long-term human safety. There is no published tolerability record to draw on, whatever a given supplier’s marketing claims.
It does not establish that AOD-9604 avoids growth hormone’s insulin and glucose effects in people, even though that’s the theoretical case for an isolated fragment. The 1993 and 2001 papers describe rats and mice, not the metabolic response of a person taking the compound.
It does not resolve its own mechanism. The 2001 mouse study needed the beta(3)-adrenergic receptor for the chronic weight-loss effect but found the drug’s direct lipolytic action doesn’t run through it, a contradiction the paper raises and leaves open.
None of this makes AOD-9604 a fraud, exactly. It means the fat-loss claim attached to it is doing something specific: borrowing the credibility of a real, citable animal literature to stand in for a human trial record that was never published, if it was ever finished at all. Strip away the marketing and what’s left is a well-run mouse study from 2001 wearing the name of a fat-loss peptide that has yet to earn its own published human trial.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
AOD-9604 Metabolic.. Current opinion in investigational drugs (London, England : 2000), 2004.
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.. Endocrinology, 2001.
Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone.. Biochemistry and molecular biology international, 1993.
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.. Lancet (London, England), 2021.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England journal of medicine, 2007.
